Torcin D0.1%+0.3%

This ophthalmic (eye) Torcin D 0.1%+0.3% is used for steroid-responsive inflammatory conditions of the eye where there is also superficial bacterial infection or a risk of bacterial infection.

• Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye where a corticosteroid is indicated and bacterial infection risk is present
• Chronic anterior uveitis
• Corneal injury from chemical, radiation, or thermal burns, or from penetrating foreign bodies, where infection risk exists

Specific approved indications may vary slightly by product; this combination is for topical ophthalmic use only.

This Torcin D 0.1%+0.3% is marketed in more than one concentration ratio of tobramycin to dexamethasone (for example, some products use tobramycin 0.3% with dexamethasone 0.1%, while others use tobramycin 0.3% with dexamethasone 0.05%), as an ophthalmic suspension or ointment. The generic name alone does not identify which specific strength or dosage form is represented. Exact strengths, excipients, and preservative content vary by product; always confirm the specific formulation on the product's own labeling.

Torcin D 0.1%+0.3% is a combination eye medicine that pairs a corticosteroid (dexamethasone) with an antibiotic (tobramycin) for topical use in the eye. It is used when there is inflammation of the eye's surface or anterior segment together with a bacterial infection or meaningful risk of one, so that the steroid can reduce inflammation while the antibiotic addresses or guards against bacterial infection. It is for ophthalmic use only and is not intended for oral or systemic use.

Therapeutic Class: Ophthalmic corticosteroid-antibiotic combination

Dexamethasone suppresses the inflammatory response of ocular tissue to a variety of inciting agents, reducing edema, cellular infiltration, and capillary dilation; it does not, however, treat the underlying infection and may delay healing. Tobramycin is an aminoglycoside antibiotic that acts against a range of gram-positive and gram-negative bacteria commonly implicated in external ocular infections. Some systemic absorption can occur with topically applied ophthalmic drugs, though this is generally limited at recommended dosing.

• Wash hands before use
• Shake the suspension well before each use, if applicable to the product
• Tilt the head back and gently pull down the lower eyelid to form a small pocket
• Instill the prescribed number of drops into the pocket without letting the dropper tip touch the eye, eyelid, or any surface, to avoid contamination
• Close the eyes gently for 1 to 2 minutes after instillation
• If using other eye drops at the same time, space them a few minutes apart
• Contact lenses should generally be removed before instillation and not reinserted until advised

No significant clinically important drug interactions have been established with normal topical ophthalmic use of Torcin D 0.1%+0.3%, since systemic absorption is generally limited. If other eye medicines are prescribed at the same time, they should be spaced apart in administration, and any concerns about combining eye medicines should be discussed with the prescribing doctor or pharmacist.

Common side effects

• Eye stinging or burning on instillation
• Eyelid itching or swelling
• Eye pain or discomfort
• Conjunctival redness (hyperemia)

Serious side effects with prolonged use

• Raised intraocular pressure, which can progress to glaucoma and optic nerve damage with prolonged use (generally 10 days or more)
• Posterior subcapsular cataract formation with long-term use
• Delayed wound healing
• Secondary ocular infection, including fungal infection, due to prolonged suppression of the host immune response

Report worsening eye pain, vision changes, or symptoms that do not improve to a doctor promptly.

Pregnancy

Torcin D 0.1%+0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be observed for signs of adrenal insufficiency (hypoadrenalism).

Breastfeeding

Systemically administered corticosteroids appear in human milk and could theoretically affect a nursing infant, but it is not known whether topical ophthalmic use results in sufficient systemic absorption to be detectable in breast milk. Caution is advised, and use should be discussed with a healthcare professional.

• Prolonged use of topical corticosteroids may result in raised intraocular pressure and glaucoma with optic nerve damage; intraocular pressure should be monitored if this product is used for more than 10 days.
• Prolonged use may also increase the risk of posterior subcapsular cataract.
• Corticosteroids can suppress the host immune response, increasing the risk of secondary ocular infection, including fungal infection, particularly with extended use.
• The product should not be used in the presence of most viral or fungal eye infections, as steroids may worsen these conditions.
• Fungal infection of the cornea should be suspected in any persistent corneal ulceration where a corticosteroid has been used.
• Not more than the prescribed quantity should be used initially, and the prescription should not be refilled without medical re-evaluation.

Topical ophthalmic overdose is uncommon but excessive or prolonged use may increase the risk of raised intraocular pressure and other steroid-related eye effects described above. If the medicine is accidentally swallowed or a large amount is applied, seek medical advice. If irritation or worsening symptoms occur after use, stop the medicine and consult a doctor.

Store as directed on the product label, typically at controlled room temperature, away from light, and tightly closed when not in use. Do not use after the labeled expiry date. Discard any unused portion after the manufacturer's recommended in-use period once opened, as this may vary by product; follow the specific product's instructions.

• Elderly: No specific dose adjustment is generally required, but monitor for intraocular pressure changes with prolonged use, as in any patient.
• Renal or hepatic impairment: Systemic absorption from topical ophthalmic use is generally limited, so specific dose adjustment is not typically required, but caution is reasonable in patients with significant systemic disease.

Treatment duration depends on clinical response and is determined by the prescribing doctor. Because prolonged corticosteroid use increases the risk of raised eye pressure and cataract, this medicine is generally not intended for extended, uninterrupted use, and intraocular pressure should be checked if treatment continues beyond about 10 days.

Drug Class: Corticosteroid (dexamethasone) combined with an aminoglycoside antibiotic (tobramycin), for topical ophthalmic use

Dexamethasone works by suppressing the release of inflammatory mediators in ocular tissue, reducing redness, swelling, and discomfort from inflammation. Tobramycin works by binding to bacterial ribosomes, disrupting bacterial protein synthesis, which kills susceptible bacteria. Combining the two allows anti-inflammatory treatment while covering or preventing a bacterial infection that corticosteroids alone could otherwise worsen.

Safety and effectiveness in children below 2 years of age have not been established. In children 2 years and older, dosing generally follows the same regimen as for adults, using the lowest effective dose and duration, under a doctor's supervision.